Two Sigma Advisers LP Reduces Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Two Sigma Advisers LP trimmed its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 32.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,300 shares of the biotechnology company's stock after selling 76,700 shares during the quarter. Two Sigma Advisers LP owned approximately 0.73% of Enanta Pharmaceuticals worth $899,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Stonepine Capital Management LLC purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $1,908,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $192,000. Millennium Management LLC increased its position in shares of Enanta Pharmaceuticals by 22.7% during the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock worth $5,158,000 after purchasing an additional 165,692 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Enanta Pharmaceuticals by 51.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock worth $1,668,000 after purchasing an additional 98,285 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Enanta Pharmaceuticals by 100.8% in the 4th quarter. BNP Paribas Financial Markets now owns 71,104 shares of the biotechnology company's stock valued at $409,000 after buying an additional 35,695 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Trading Up 1.4%

ENTA traded up $0.10 during mid-day trading on Thursday, hitting $7.21. 99,174 shares of the stock were exchanged, compared to its average volume of 285,883. The firm's fifty day moving average is $5.45 and its two-hundred day moving average is $6.23. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.09 and a 1-year high of $17.24. The company has a market cap of $154.13 million, a PE ratio of -1.46 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The firm had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. As a group, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ENTA. JMP Securities upped their target price on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a report on Tuesday. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.